QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jmp-securities-downgrades-athira-pharma-to-market-perform

JMP Securities analyst Jason Butler downgrades Athira Pharma (NASDAQ:ATHA) from Market Outperform to Market Perform.

 btig-downgrades-athira-pharma-to-neutral

BTIG analyst Thomas Shrader downgrades Athira Pharma (NASDAQ:ATHA) from Buy to Neutral.

 athira-pharmas-alzheimers-candidate-fails-to-improve-cognition-and-function-in-patients-with-mildmoderate-disease-stock-sinks

Athira Pharma stock falls as the company reports mixed results from its Phase 2/3 LIFT-AD clinical trial for Alzheimer's tr...

 athira-pharma-shares-resume-trade
Athira Pharma Shares Resume Trade
09/03/2024 20:30:59

 rodman--renshaw-initiates-coverage-on-athira-pharma-with-buy-rating-announces-price-target-of-22

Rodman & Renshaw analyst Elemer Piros initiates coverage on Athira Pharma (NASDAQ:ATHA) with a Buy rating and announces ...

 athira-pharma-q2-eps-070-beats-074-estimate

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.74)...

 athira-pharma-to-present-preclinical-data-demonstrating-new-insights-into-the-mechanism-by-which-fosgonimeton-protects-neurons-from-alzheimers-disease-related-pathology-at-aaic-2024

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms t...

 jmp-securities-reiterates-market-outperform-on-athira-pharma-maintains-19-price-target

JMP Securities analyst Jason Butler reiterates Athira Pharma (NASDAQ:ATHA) with a Market Outperform and maintains $19 price ...

 athira-pharma-advances-als-drug-with-successful-phase-1-trial-in-healthy-volunteers

BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical co...

 jmp-securities-reiterates-market-outperform-on-athira-pharma-maintains-19-price-target

JMP Securities analyst Jason Butler reiterates Athira Pharma (NASDAQ:ATHA) with a Market Outperform and maintains $19 price ...

 athira-pharma-q1-2024-gaap-eps-069-beats-078-estimate

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.78)...

 athira-pharma-announces-publication-of-preclinical-data-highlighting-fosgonimeton-treatment-in-models-of-alzheimers-disease

Key findings reported in the study publication regarding fosgonimeton in preclinical models of Alzheimer's disease include:...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION